Latest Healthcare News

HealthCo Healthcare and Wellness REIT reported a substantial $89.3 million loss for FY25, driven by tenant payment issues and portfolio downsizing, leading to suspended distributions and a debt facility extension.

WAM Capital Limited reported a robust 22.2% investment portfolio return for FY2025, outperforming key ASX benchmarks and maintaining its full-year dividend at 15.5 cents per share with a 10% yield.

Pro Medicus Limited reports a record-breaking year with $520 million in new contracts and a surge in cloud adoption, setting the stage for continued growth. The company also advances its AI and cardiology offerings, reinforcing its market position.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the fiscal year ending June 30, 2025, signaling steady returns for shareholders.

Pro Medicus Limited has delivered a record-breaking FY2025 with soaring profits and a wave of major US healthcare contracts, setting the stage for continued expansion.

Pro Medicus Limited has reported a robust FY25 with revenue climbing nearly 32% and net profit up 39%, prompting a significant dividend increase.

Bailador Technology Investments reported a solid FY25 with a 7.8% post-tax portfolio return and a fully franked final dividend of 3.6 cents per share, underpinned by strong growth in private tech investments and strategic realisations.

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.

Bailador Technology Investments reported a solid $19.3 million net profit for FY25, declared a fully-franked dividend yielding 8.1% grossed-up, and deployed $40.8 million into expanding its fast-growing tech portfolio.

Bailador Technology Investments reported a $19.25 million net profit for FY25, down 7%, while its private portfolio surged with a 33% internal rate of return. The company declared a fully franked 3.6 cent dividend, underscoring confidence in its growth strategy.

Pacific Smiles Group has reported solid FY25 financial results, with patient fees rising 8.7% and underlying EBITDA up 12.1%, reflecting strong operational momentum.

Atomo Diagnostics has successfully placed $416,611.77 from its Share Purchase Plan shortfall, bolstered by a recent US order from Lumos Diagnostics. This capital injection strengthens Atomo’s position as it scales up production of its Pascal cassettes.